Want to see WVE full AI Analyst Report?
Total Valuation
Wave Life Sciences has a market cap or net worth of $1.20B. The enterprise value is $738.28.
Market Cap$1.20B
Enterprise Value$738.28
Share Statistics
Wave Life Sciences has 197,048,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding197,048,170
Owned by Insiders28.50%
Owned by Institutions―
Financial Efficiency
Wave Life Sciences’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -39.03%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-39.03%
Return on Capital Employed (ROCE)-0.40
Revenue Per Employee134.79K
Profits Per Employee-644.73K
Employee Count317
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Wave Life Sciences is ―. Wave Life Sciences’s PEG ratio is -0.19.
PE Ratio―
PS Ratio67.10
PB Ratio5.45
Price to Fair Value5.45
Price to FCF-15.29
Price to Operating Cash Flow-5.52
PEG Ratio-0.19
Income Statement
In the last 12 months, Wave Life Sciences had revenue of 42.73M and earned -204.38M in profits. Earnings per share was -1.21.
Revenue42.73M
Gross Profit33.88M
Operating Income-215.38M
Pretax Income-204.38M
Net Income-204.38M
EBITDA-195.53M
Earnings Per Share (EPS)-1.21
Cash Flow
In the last 12 months, operating cash flow was -184.68M and capital expenditures -1.56M, giving a free cash flow of -186.24M billion.
Operating Cash Flow-184.68M
Free Cash Flow-186.24M
Free Cash Flow per Share-0.95
Dividends & Yields
Wave Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.13
52-Week Price Change-40.30%
50-Day Moving Average5.90
200-Day Moving Average9.53
Relative Strength Index (RSI)32.67
Average Volume (3m)2.75M
Important Dates
Wave Life Sciences upcoming earnings date is Nov 5, 2026, TBA (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Wave Life Sciences as a current ratio of 6.47, with Debt / Equity ratio of 9.61%
Current Ratio6.47
Quick Ratio6.47
Debt to Market Cap0.00
Net Debt to EBITDA2.99
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Wave Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Wave Life Sciences EV to EBITDA ratio is -11.67, with an EV/FCF ratio of -12.18.
EV to Sales53.43
EV to EBITDA-11.67
EV to Free Cash Flow-12.18
EV to Operating Cash Flow-12.18
Balance Sheet
Wave Life Sciences has $490.60M in cash and marketable securities with $43.59M in debt, giving a net cash position of $447.01M billion.
Cash & Marketable Securities$490.60M
Total Debt$43.59M
Net Cash$447.01M
Net Cash Per Share$2.27
Tangible Book Value Per Share$3.12
Margins
Gross margin is 96.54%, with operating margin of -504.09%, and net profit margin of -478.33%.
Gross Margin96.54%
Operating Margin-504.09%
Pretax Margin-478.33%
Net Profit Margin-478.33%
EBITDA Margin-457.62%
EBIT Margin-478.33%
Analyst Forecast
The average price target for Wave Life Sciences is $20.54, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$20.54
Price Target Upside253.50% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast-30.42%
EPS Growth Forecast-23.31%